A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates

Vivek Thumbigere-Math, Lam Tu, Sabrina Huckabay, Arkadiusz Z. Dudek, Scott Lunos, David L. Basi, Pamela Hughes, Joseph W. Leach, Karen K. Swenson, Rajaram Gopalakrishnan

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Objective: To evaluate the frequency, risk factors, and clinical presentation of bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ). STUDY DESIGN: We performed a retrospective analysis of 576 patients with cancer treated with intravenous pamidronate and/or zoledronate between January, 2003 and December, 2007 at the University of Minnesota Masonic Cancer Center and Park Nicollet Institute. Results: Eighteen of 576 identified patients (3.1%) developed BRONJ including 8 of 190 patients (4.2%) with breast cancer, 6 of 83 patients (7.2%) with multiple myeloma, 2 of 84 patients (2.4%) with prostate cancer, 1 of 76 patients (1.3%) with lung cancer, 1 of 52 patients (1.9%) with renal cell carcinoma, and in none of the 73 patients with other malignancies. Ten patients (59%) developed BRONJ after tooth extraction, whereas 7 (41%) developed it spontaneously (missing data for 1 patient). The mean number of BP infusions (38.1±19.06 infusions vs. 10.5±12.81 infusions; P

Original languageEnglish (US)
Pages (from-to)386-392
Number of pages7
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume35
Issue number4
DOIs
StatePublished - Aug 2012
Externally publishedYes

Fingerprint

Osteonecrosis
Diphosphonates
Jaw
Retrospective Studies
Neoplasms
zoledronic acid
pamidronate
Bisphosphonate-Associated Osteonecrosis of the Jaw
Tooth Extraction
Multiple Myeloma
Renal Cell Carcinoma
Lung Neoplasms
Prostatic Neoplasms
Breast Neoplasms

Keywords

  • bisphosphonate
  • breast cancer
  • diabetes
  • hypothyroidism
  • multiple myeloma
  • osteonecrosis
  • osteonecrosis of the jaw
  • pamidronate
  • zoledronate

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. / Thumbigere-Math, Vivek; Tu, Lam; Huckabay, Sabrina; Dudek, Arkadiusz Z.; Lunos, Scott; Basi, David L.; Hughes, Pamela; Leach, Joseph W.; Swenson, Karen K.; Gopalakrishnan, Rajaram.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 35, No. 4, 08.2012, p. 386-392.

Research output: Contribution to journalArticle

Thumbigere-Math, Vivek ; Tu, Lam ; Huckabay, Sabrina ; Dudek, Arkadiusz Z. ; Lunos, Scott ; Basi, David L. ; Hughes, Pamela ; Leach, Joseph W. ; Swenson, Karen K. ; Gopalakrishnan, Rajaram. / A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2012 ; Vol. 35, No. 4. pp. 386-392.
@article{a840c114ac144c5c989864b74cb29282,
title = "A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates",
abstract = "Objective: To evaluate the frequency, risk factors, and clinical presentation of bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ). STUDY DESIGN: We performed a retrospective analysis of 576 patients with cancer treated with intravenous pamidronate and/or zoledronate between January, 2003 and December, 2007 at the University of Minnesota Masonic Cancer Center and Park Nicollet Institute. Results: Eighteen of 576 identified patients (3.1{\%}) developed BRONJ including 8 of 190 patients (4.2{\%}) with breast cancer, 6 of 83 patients (7.2{\%}) with multiple myeloma, 2 of 84 patients (2.4{\%}) with prostate cancer, 1 of 76 patients (1.3{\%}) with lung cancer, 1 of 52 patients (1.9{\%}) with renal cell carcinoma, and in none of the 73 patients with other malignancies. Ten patients (59{\%}) developed BRONJ after tooth extraction, whereas 7 (41{\%}) developed it spontaneously (missing data for 1 patient). The mean number of BP infusions (38.1±19.06 infusions vs. 10.5±12.81 infusions; P",
keywords = "bisphosphonate, breast cancer, diabetes, hypothyroidism, multiple myeloma, osteonecrosis, osteonecrosis of the jaw, pamidronate, zoledronate",
author = "Vivek Thumbigere-Math and Lam Tu and Sabrina Huckabay and Dudek, {Arkadiusz Z.} and Scott Lunos and Basi, {David L.} and Pamela Hughes and Leach, {Joseph W.} and Swenson, {Karen K.} and Rajaram Gopalakrishnan",
year = "2012",
month = "8",
doi = "10.1097/COC.0b013e3182155fcb",
language = "English (US)",
volume = "35",
pages = "386--392",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates

AU - Thumbigere-Math, Vivek

AU - Tu, Lam

AU - Huckabay, Sabrina

AU - Dudek, Arkadiusz Z.

AU - Lunos, Scott

AU - Basi, David L.

AU - Hughes, Pamela

AU - Leach, Joseph W.

AU - Swenson, Karen K.

AU - Gopalakrishnan, Rajaram

PY - 2012/8

Y1 - 2012/8

N2 - Objective: To evaluate the frequency, risk factors, and clinical presentation of bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ). STUDY DESIGN: We performed a retrospective analysis of 576 patients with cancer treated with intravenous pamidronate and/or zoledronate between January, 2003 and December, 2007 at the University of Minnesota Masonic Cancer Center and Park Nicollet Institute. Results: Eighteen of 576 identified patients (3.1%) developed BRONJ including 8 of 190 patients (4.2%) with breast cancer, 6 of 83 patients (7.2%) with multiple myeloma, 2 of 84 patients (2.4%) with prostate cancer, 1 of 76 patients (1.3%) with lung cancer, 1 of 52 patients (1.9%) with renal cell carcinoma, and in none of the 73 patients with other malignancies. Ten patients (59%) developed BRONJ after tooth extraction, whereas 7 (41%) developed it spontaneously (missing data for 1 patient). The mean number of BP infusions (38.1±19.06 infusions vs. 10.5±12.81 infusions; P

AB - Objective: To evaluate the frequency, risk factors, and clinical presentation of bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ). STUDY DESIGN: We performed a retrospective analysis of 576 patients with cancer treated with intravenous pamidronate and/or zoledronate between January, 2003 and December, 2007 at the University of Minnesota Masonic Cancer Center and Park Nicollet Institute. Results: Eighteen of 576 identified patients (3.1%) developed BRONJ including 8 of 190 patients (4.2%) with breast cancer, 6 of 83 patients (7.2%) with multiple myeloma, 2 of 84 patients (2.4%) with prostate cancer, 1 of 76 patients (1.3%) with lung cancer, 1 of 52 patients (1.9%) with renal cell carcinoma, and in none of the 73 patients with other malignancies. Ten patients (59%) developed BRONJ after tooth extraction, whereas 7 (41%) developed it spontaneously (missing data for 1 patient). The mean number of BP infusions (38.1±19.06 infusions vs. 10.5±12.81 infusions; P

KW - bisphosphonate

KW - breast cancer

KW - diabetes

KW - hypothyroidism

KW - multiple myeloma

KW - osteonecrosis

KW - osteonecrosis of the jaw

KW - pamidronate

KW - zoledronate

UR - http://www.scopus.com/inward/record.url?scp=84864374386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864374386&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3182155fcb

DO - 10.1097/COC.0b013e3182155fcb

M3 - Article

C2 - 22561331

AN - SCOPUS:84864374386

VL - 35

SP - 386

EP - 392

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -